Literature DB >> 29066164

Eculizumab: a treatment option for myasthenia gravis?

Nils Erik Gilhus1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29066164     DOI： 10.1016/S1474-4422(17)30363-0

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  6 in total

Review 1.  The emerging role of complement in neuromuscular disorders.

Authors:  John D Lee; Trent M Woodruff
Journal:  Semin Immunopathol       Date:  2021-10-27       Impact factor: 9.623

2.  Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy.

Authors:  Nicola Iacomino; Fiammetta Vanoli; Rita Frangiamore; Marta Ballardini; Letizia Scandiffio; Federica Bortone; Francesca Andreetta; Fulvio Baggi; Pia Bernasconi; Carlo Antozzi; Paola Cavalcante; Renato Mantegazza
Journal:  Biomedicines       Date:  2022-06-09

Review 3.  Myasthenia gravis and infectious disease.

Authors:  Nils Erik Gilhus; Fredrik Romi; Yu Hong; Geir Olve Skeie
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849

Review 4.  Eculizumab: A Review in Generalized Myasthenia Gravis.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 5.  A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature.

Authors:  Maria Elena Farrugia; John A Goodfellow
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

Review 6.  Complement Inhibition for the Treatment of Myasthenia Gravis.

Authors:  Renato Mantegazza; Fiammetta Vanoli; Rita Frangiamore; Paola Cavalcante
Journal:  Immunotargets Ther       Date:  2020-12-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.